Clinical Trials
17 trialsNCT03050268 2026-04-23
SJFAMILY
St. Jude Children's Research Hospital
Recruiting
NCT03114319 2026-04-16
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
Novartis
Phase 1 Terminated
NCT04670679 2026-03-25
FLAGSHP-1
Erasca, Inc.
Phase 1 Active not recruiting
NCT05361811 2026-02-19
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial
National Institutes of Health Clinical Center (CC)
Phase NA Recruiting
NCT04045496 2025-12-29
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1 Completed
NCT04395495 2025-12-18
RASopathy Biorepository
Children's Hospital Medical Center, Cincinnati
Recruiting
NCT04121286 2025-05-20
A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
Allist Pharmaceuticals, Inc.
Phase 1 Completed
NCT03518554 2024-12-16
A First in Human, Dose Escalation Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1 Completed
NCT03565003 2024-09-25
A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2 Completed
NCT05761314 2024-04-04
4218
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase NA Recruiting
NCT03504501 2023-11-30
SynCoRAS
Technical University of Munich
Phase 2 Terminated
NCT04463316 2023-09-06
GROW UR GENES
Erasmus Medical Center
Recruiting
NCT04959981 2023-07-25
HERKULES-2
Erasca, Inc.
Phase 1 Completed
NCT03989115 2023-06-26
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Revolution Medicines, Inc.
Phase 1/2 Completed
NCT05715398 2023-02-10
BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer
Shanghai Gopherwood Biotech Co., Ltd.
Phase 1/2 Unknown
NCT04252339 2023-01-31
RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT03634982 2022-09-01
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Phase 1 Unknown